Boston Scientific (NYSE:BSX) Rating Lowered to Neutral at JPMorgan Chase & Co.
Boston Scientific said higher China pricing pressure and weaker heart-device sales will limit growth, while a cyberattack cut third-quarter revenue by about $150 million.
- On Wednesday, Boston Scientific lowered its full-year profit forecast and delayed its $14.5 billion acquisition of Penumbra to early 2027, citing regulatory reviews and operational challenges.
- A cyberattack caused a roughly $150 million revenue hit in the third quarter, while Watchman sales declined 6% and electrophysiology fell 5%, pressuring the company's $5.14 billion total revenue.
- Boston Scientific cut its 2026 adjusted earnings per share guidance to $3.16 to $3.18 from a prior range of $3.28 to $3.32, causing shares to fall nearly 7% to $42.02 Wednesday.
- CFO Jon Monson stated, "We anticipate continued top-line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earnings per share."
- CEO Mike Mahoney warned of price headwinds in China through 2027, while higher interest rates increase financing costs for the Penumbra purchase, further pressuring earnings growth.
13 Articles
13 Articles
Stock Market Today, Oct. 28: Boston Scientific Slips 6% After Cutting Q4 Sales and Full-Year EPS Guidance on Cyberattack Impact
Today, Oct. 28, 2026, the medical device maker slashed profit expectations after an August cyberattack continued disrupting operations.
Boston Scientific warns of tough 2027 on China pricing, heart-device weakness - Regional Media News
By Padmanabhan Ananthan Oct 28 (Reuters) - Boston Scientific lowered its full-year profit forecast on Wednesday and warned that revenue and earnings growth could be challenging in 2027, citing pricing pressure in China and weakness in its key heart-device businesses. Shares of the company were [...]
Boston Scientific warns of tough 2027 on China pricing, heart-device weakness
By Padmanabhan Ananthan Oct 28 (Reuters) – Boston Scientific lowered its full-year profit forecast on Wednesday and warned that revenue and earnings growth could be challenging in 2027, citing pricing pressure in China and weakness in its key heart-device businesses. Shares of the company were down 5.3% by afternoon. “We anticipate continued top-line pressure into 2027, which we expect will make it challenging to grow revenue and adjusted earn…
Coverage Details
Bias Distribution
- 45% of the sources are Center, 44% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
![[Opinion] Bornauw Critical of Bruno at Anderlecht: “Experimented Too Much”](/_next/image?url=%2F_next%2Fstatic%2Fmedia%2Fgeneric_2_half.ff1d69ce.webp&w=1440&q=75)
